A biomanufacturing facility in Everett that Pfizer decided to shut down before it opened is getting a new lease on life, with ...

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum ...

The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront and ...

For circular systems to succeed, the entire ecosystem must work. Biopharma recycling is a chain of interconnected activities: ...

Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - ...

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applicationsCompleted a $50 million private placement (PIPE) to further fund clinical development and ...

Sentynl holds an exclusive U.S. commercialization option for AATD-LD, while securing global manufacturing rights; Mereo retains commercial rights outside the U.S. and leads Phase III execution.

Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination ...

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27,2027 - ...